This is noteworthy because conventional approaches have demonstrated a protective role of PPARγ agonists and a conflicting (both protective and exacerbating) role of PPARα in IBD;15,17,18,73 the advantage of dual agonism has neither been rationalized nor tested. This evidence concerns the gene PPARG and inflammatory bowel disease.